Status: Active – Not Recruiting patients
A Phase 1 trial entitled KEYNOTE-200 or STORM (Systemic Treatment Of Resistant Metastatic disease) currently underway. It is a two part study as follows:
- VLA-009A conducted in the UK employs CAVATAK® intravenously as a monotherapy in patients with late stage solid tumors including Non-Small Cell Lung Cancer (NSCLC), Castrate-Resistant Prostate Cancer, Melanoma and Bladder Cancer.
- VLA-009B / KEYNOTE-200 conducted in the US and UK, in collaboration with Merck, employs intravenous use of CAVATAK with pembrolizumab (Keytruda®) in patients with NSCLC and Bladder Cancer with the aim to evaluate the safety and efficacy of this novel immunotherapy combination.
For further information about this trial, please visit the Clinical Trial website at ClinicalTrials.gov Identifier: NCT02043665